Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bill Ackman 'has killed Pershing Square. Its over'- Hempton (VRX)
November 23, 2015 6:03 PM ESTJohn Hempton says Bill Ackman "has killed Pershing Square. Its over." following news the firm raised its stake in Valeant Pharmaceuticals (NYSE: VRX) to 9.9%.
Bill Ackman has killed Pershing Square. Its over... https://t.co/1pp5XSHRme
John_Hempton (@John_Hempton) November 23, 2015... MoreExclusive: ValueAct gains for the year wiped out by Valeant loss
November 23, 2015 5:48 PM ESTBy Michael Flaherty
(Reuters) - Activist investor ValueAct Capital said its fund fell 8.3 percent during the third quarter, wiping out its gains for the year, hurt by a plunge in shares of its main portfolio company, Valeant Pharmaceuticals International Inc (NYSE: VRX).
For the nine months ending on Sept. 30, the ValueAct Capital Master Fund was down 0.9 percent, ValueAact said in a letter to investors which was seen by Reuters on Monday. As of the second quarter, the fund had been up 8 percent for the year.
ValueAct also said it... More
Ackman boosts stake in drugmaker Valeant
November 23, 2015 5:44 PM EST(Reuters) - Activist investor Bill Ackman's hedge fund has significantly increased its investment in Valeant Pharmaceuticals International (NYSE: VRX), and signaled it may play a greater role in the beleaguered drugmakers strategy, according to a regulatory filing.
Ackman's Pershing Square Capital Management raised its stake in Valeant to 9.9 percent from 5.7 percent reported in March, according to a filing on Monday with the U.S. Securities and Exchange Commission. Shares in the company rose 3.1 percent in after-hours trading.
Pershing noted in its filing that it may conduct... More
Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%
November 23, 2015 5:28 PM ESTPershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd. has updated its Schedule 13D with the United States Securities and Exchange Commission, disclosing that various funds it manages increased their beneficial ownership of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), to 9.9% of shares outstanding.
... MoreMarket Wrap: Pfizer, Allergan Make it Offiical; Icahn Gets Active on Xerox; Existing Sales Slump in Oct.
November 23, 2015 5:26 PM ESTMarket wrap for November 23rd
End of the Day: S&P 500 down 2.6 to 2,086.59; Dow Jones down to 17,792.68; Nasdaq down 2.4 to 5,102.48
Market Brief: Markets ended lower to start off the holiday-shortened week with most investors now looking to a December rate hike from the Fed. Trading on the session was notably light.
Existing home sales slipped in October, missing consensus estimates in the process.
Pfizer and Allergan announced a massive merger agreement, bolstering a slew of other M&A... More
Ackman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
November 23, 2015 5:17 PM ESTIn an amended 13D filing on Valeant Pharmaceuticals (NYSE: VRX), Bill Ackman's hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
For more notable holders of Valeant Pharmaceuticals stock click here. For more information on Pershing Square Capital click... More
Ackman's Pershing Square Moves Stake in Valeant Pharma (VRX) to 9.9%
November 23, 2015 5:17 PM ESTIn an amended 13D filing on Valeant Pharma (NYSE: VRX), Bill Ackman's hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
More from the amended filing:
The Reporting Persons hold their stake in the Issuer for investment purposes. Representatives of the Reporting Persons may conduct discussions from time to time with management of the Issuer, other stockholders of the Issuer and/or other relevant... More
Pershing Square Capital Raises Stake in Valeant Pharma (VRX) to 9.9%
November 23, 2015 5:16 PM ESTIn a 13D filing on Valeant Pharma (NYSE: VRX), hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
For more notable... More
Hedge funds' favorite stocks lag broader market: Goldman data
November 23, 2015 4:29 PM ESTBy Svea Herbst-Bayliss
BOSTON (Reuters) - Hedge fund managers' favorite stocks stumbled hard this year to post their worst returns since the financial crisis with health-care companies, such as Valeant Pharmaceuticals (NYSE: VRX), leading the way lower, according to new data from Goldman Sachs.
Goldman analysts calculated that the basket of managers' 50 most heavily owned stocks - among which are Allergan (NYSE: AGN), Facebook (NASDAQ: FB), Netflix (NASDAQ: NFLX) and Cheniere Energy (NYSE:... More
Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week
November 23, 2015 10:43 AM ESTShort seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:
Citi launched coverage on the... More